BTCYOTCSurgical & Medical Instruments & ApparatusFiscal year ends March 31

BIOTRICITY INC.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026

$0.05+0.00 (+8.70%)

Close on Oct 19, 2026

Market cap: $1.15M
P/E (TTM): –
Dividend yield: –

Dividends

Biotricity has not reported a dividend

No dividend per share appears in Biotricity's annual filings since fiscal 2013.

Where these numbers come from

Parsed from the XBRL in Biotricity's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-6 reverse split on Nov 14, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BTCY.

Revenue growth13.4% · median 53.4%

Gross margin81.5% · median 36.0%

Operating margin9.6% · median -322.8%

Net margin-16.4% · median -327.0%

Company	Revenue	Growth
KMTS	$106.73M	+60.7%
DRIO	$21.00M	-22.6%
BTCY	$16.40M	+13.4%
NSPR	$10.84M	+53.4%
NONE.	$6.45M	–
PLSM	–	–

Company

Exchange: OTC
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: March 31
Employees: 46
Held by institutions: 0.2%
Auditor: SRCO Professional Corporation
SEC CIK: 1630113

Advertisement
300 × 250